Overall PRPH gets a fundamental rating of 0 out of 10. We evaluated PRPH against 191 industry peers in the Pharmaceuticals industry. PRPH has a bad profitability rating. Also its financial health evaluation is rather negative. PRPH has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.22% | ||
| ROE | -777.79% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.94 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.3626
-0.08 (-18.97%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.36 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -81.22% | ||
| ROE | -777.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.84% | ||
| Cap/Sales | 3.47% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.14 | ||
| Altman-Z | -3.94 |
ChartMill assigns a fundamental rating of 0 / 10 to PRPH.
ChartMill assigns a valuation rating of 0 / 10 to PROPHASE LABS INC (PRPH). This can be considered as Overvalued.
PROPHASE LABS INC (PRPH) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of PROPHASE LABS INC (PRPH) is expected to grow by 97.56% in the next year.
The dividend rating of PROPHASE LABS INC (PRPH) is 0 / 10 and the dividend payout ratio is 0%.